"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to TNGX. [ FAQ on what and how to ask] For non-TNGX questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Dr. Malte Peters M.D.
Headquarter: 201 Brookline Avenue, Suite 901, Boston, MA, United States, 02215
Industry: Biotechnology, Investment Track: Precision Oncology - Protein, Employees: 137
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
My Watchlist
